Keywords: Seattle Genetics, GlaxoSmithKline, ADC technoilogy, chemotherapy, Licensing, Monoclonal antibodies
Seattle Genetics in deal with GSK for ADC worth up to $402 million
Article | 22 December 2009
US biotechnology firm Seattle Genetics has secured an initial $12 million from UK drug giant GlaxoSmithKline under which GSK will acquire the rights to utilize the firm’s antibody-drug conjugate (ADC) technology with multiple antigens to be named by GSK.
“By collaborating with leading companies such as GSK, we are broadening the reach of our proprietary ADC technology while also generating substantial non-dilutive capital for Seattle Genetics,” said Eric Dobmeier, chief business officer of Seattle Genetics. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
